Company / Interest Expense
Larimar Therapeutics, Inc. Interest Expense History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$165.0K
FY2019
5-year range
$165.0K / $870.0K
FY2015-FY2019
Trend
-68.8%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Interest Expense has declined for 3 consecutive years, from $870,000 in FY2016 to $165,000 in FY2019.
Based on SEC 10-K filings.
$165,000 in FY2019 with a 5-year CAGR of +11.2%.
Improved from $806,000 to $165,000 over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -42.5%
- 5-Year CAGR
- +11.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- Larimar Therapeutics, Inc.'s interest expense has declined for 3 consecutive years.
- 5-year CAGR of +11.2%, indicating consistent growth.
- In FY2019, interest expense decreased 68.8% year-over-year.
- Peak interest expense was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $165.0K | -68.8% |
| FY2018 | $529.0K | -34.4% |
| FY2017 | $806.0K | -7.4% |
| FY2016 | $870.0K | +0.0% |
| FY2015 | $870.0K | +796.9% |
| FY2014 | $97.0K | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026